We treated 15 patients with advanced B-cell malignancies. Nine patients had diffuse large B-cell lymphoma (DLBCL), two had indolent lymphomas, and four had chronic lymphocytic leukemia. Patients ...
MILAN, June 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting ...
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied.
Odronextamab demonstrated a manageable safety profile and generated durable responses in patients with R/R DLBCL who have progressed after CAR-T therapy. Among patients with relapsed/refractory (R/R) ...
Please provide your email address to receive an email when new articles are posted on . Most patients in a phase 2 trial responded to a non-cryopreserved tandem CAR-T. Most trial participants received ...
CD19-directed CAR T-cell therapy can lead to sustained remission in DLBCL, but relapse is common, affecting up to 60% of patients. Epcoritamab, a bispecific T-cell engager, may enhance CAR T-cell ...
Unlike conventional CAR-T, which carries a ~50% risk of cytokine release syndrome (CRS) and neurotoxicity, this novel therapeutic approach demonstrated complete absence of: Cytokine release syndrome ...
H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR ...
Body composition analysis, especially skeletal muscle to visceral fat ratio, predicts treatment outcomes in relapsed/refractory DLBCL patients treated with loncastuximab tesirine. PET/CT scans with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results